Medical uses:

Nulibry, also known as cyclic pyranopterin monophosphate (cPMP), is used to lower the risk of death in patients with molybdenum cofactor deficiency (MoCD) Type A.

Recommended Dosage:

• Initiation: Begin Nulibry therapy upon diagnosis or presumptive diagnosis of MoCD Type A. Confirm the diagnosis promptly after starting treatment. If genetic testing does not confirm MoCD Type A, discontinue Nulibry.
• Administration: Nulibry should be administered by a healthcare professional. If deemed appropriate, a caregiver may administer it at home. It is for intravenous infusion only, using non-DEHP tubing with a 0.2 micron filter. Do not mix with other medications or infuse with other drugs.
• Infusion Rate: Administer Nulibry via an infusion pump at 1.5 mL/minute. For doses less than 2 mL, use a slow intravenous push. Administer within four hours of reconstitution.

Dosage for Patients Less Than One Year of Age (by gestational age):

• Preterm Neonates (Gestational Age < 37 Weeks):
  • Initial: 0.4 mg/kg once daily
  • Month 1: 0.7 mg/kg once daily
  • Month 3: 0.9 mg/kg once daily
• Term Neonates (Gestational Age ≥ 37 Weeks):
  • Initial: 0.55 mg/kg once daily
  • Month 1: 0.75 mg/kg once daily
  • Month 3: 0.9 mg/kg once daily

Dosage for Patients One Year of Age or Older:

• For patients aged 1 year and above, the recommended dose is 9.5 mg/kg of fosdenopterin, based on actual body weight. This should be given as an intravenous infusion once daily.

Missed Dose Instructions:

• If a dose of Nulibry is missed, administer it as soon as possible. Ensure that the next scheduled dose is given at least six hours after the missed dose.

Warnings & Precautions:

Patients treated with Nulibry should avoid or limit exposure to direct sunlight and artificial UV light. Precautionary measures include wearing protective clothing and hats, using broad-spectrum sunscreen with high SPF for patients aged 6 months and older, and wearing sunglasses. If photosensitivity occurs, seek medical attention promptly and consider a dermatological evaluation.

Other medications, including prescription and over-the-counter drugs, vitamins, and herbal products, may interact with Nulibry. Inform your healthcare provider about all current medications and any new medications your child starts or stops using.

There is no data on the use of Nulibry in pregnant women to assess the risk of birth defects, miscarriage, or adverse maternal or fetal outcomes. Similarly, there is no information on the presence of Nulibry or its metabolites in human milk, its effects on the breastfed infant, or its impact on milk production.

When considering Nulibry treatment for nursing mothers, weigh the developmental and health benefits of breastfeeding against the mother’s clinical need for Nulibry and any potential side effects on the breastfed infant from the treatment or the underlying maternal condition.

Documentation & Availability :

Documents  required to import NULIBRY  to India? 

NULIBRY (fosdenopterin) injection can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:

1. 2 ID proofs along with PAN card details along with attested scanned copies
2. Valid doctor prescription scanned copy
3. Doctor’s MCI number
4. Doctor’s mobile number
5. Patients diagnostic reports

How is the order confirmed? 

The order will be confirmed only after the receipt of:

1. The above-mentioned documents and drug availability.
2. Import permit if applicable.

Sourcing & Delivery:

The Rx4U team has extensive experience in sourcing  NULIBRY (Cancer Treatment Medicines) from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.

 FAQ:

What is the Generic Name for the trade name drug Nulibry®?

Fosdenopterin is Generic Name for the trade name drug Nulibry®.

What is the Manufacturer Name of Nulibry®?

Nulibry® is manufactured by BridgeBio Pharma, Inc.

Is Nulibry® approved by the FDA?

Yes, Nulibry® is approved by the FDA. Date of first/initial approval: February 26, 2021.

Where can I get Nulibry 9.5 mg injection at the best price in India?

To get the best nulibry 9.5 injection price in India, kindly contact Rx4u team.

What is the dosage and form of Nulibry® supplied?

Nulibry® is supplied as injection: 9.5 mg of fosdenopterin as a lyophilized powder or cake in a single-dose vial for reconstitution for intravenous administration. 

What are the most common side effects with Nulibry®? 

The most common side effects with Nulibry include: catheter-related complications, viral infection, pyrexia, pneumonia, cough/sneezing, otitis media, bacteremia, vomiting, viral upper respiratory infection, gastroenteritis, and diarrhea. 

How much does Nulibry® cost in India?

The nulibry cost in India is less and can vary. In order to procure this medication authentically, you can reach out to Rx4u team.

What are the storage conditions of Nulibry®?

Store Nulibry in a medical-grade freezer. Keep all the vials in their original carton in order to protect them from light. Check the temperature of the −13°F to 14°F (−25°C to −10°C) freezer on a regular basis to make sure it’s working appropriately.

Is it safe to buy Fosdenopterin injection online from India?

Yes, you can buy fosdenopterin injection online at best price from https://rx4u.in/

*Disclaimer

All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.